Home » Stocks » YMAB

Y-mAbs Therapeutics, Inc. (YMAB)

Stock Price: $42.30 USD -0.97 (-2.24%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.69B
Revenue (ttm) n/a
Net Income (ttm) -113.63M
Shares Out 40.01M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE 31.35
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $42.30
Previous Close $43.27
Change ($) -0.97
Change (%) -2.24%
Day's Open 42.38
Day's Range 41.43 - 43.08
Day's Volume 141,439
52-Week Range 14.16 - 50.49

More Stats

Market Cap 1.69B
Enterprise Value 1.54B
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 40.01M
Float 24.63M
EPS (basic) -2.98
EPS (diluted) -2.99
FCF / Share -2.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.92M
Short Ratio 17.42
Short % of Float 11.86%
Beta 1.35
PE Ratio n/a
Forward PE 31.35
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.96
Revenue n/a
Operating Income -115.32M
Net Income -113.63M
Free Cash Flow -97.16M
Net Cash 156.09M
Net Cash / Share 3.90
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -49.14%
ROE -89.34%
ROIC 2,641.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(12.58% upside)
Current: $42.30
Target: 47.62
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-83.00-43.23-19.24-17.04
Net Income-81.03-43.27-19.16-17.06
Shares Outstanding35.1828.7719.4014.09
Earnings Per Share-2.30-1.50-0.99-1.21
Operating Cash Flow-73.50-41.23-15.87-11.17
Capital Expenditures-1.97-0.23--
Free Cash Flow-75.46-41.46-15.87-11.17
Cash & Equivalents20714890.5216.90
Total Debt2.23---
Net Cash / Debt20514890.5216.90
Book Value19914182.1512.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Y-mAbs Therapeutics, Inc.
Country United States
Employees 65
CEO Claus Juan Møller-San Pedro

Stock Information

Ticker Symbol YMAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: YMAB
IPO Date September 21, 2018


Y-mAbs Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.